Mutagenic and carcinogenic properties of platinum-based anticancer drugs

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 355, Issue 1-2, 1996, Pages 59-70

  Sanderson, Barbara J S ^a   Ferguson, Lynnette R ^b   Denny, William A ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

anticancer drug; cancer; carboplatin; cisplatin; mutation

Indexed keywords

CARBOPLATIN; CISPLATIN; IPROPLATIN; MIBOPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; SPIROPLATIN; TETRAPLATIN; TRANSPLATIN; ZENIPLATIN;

CARCINOGENICITY; DNA REPAIR; HUMAN; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030591670     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/0027-5107(96)00022-X     Document Type: Article

References (59)

1. Ashby, J., H. Tinwell, P. Glover, P. Poorman-Allen, R. Krehl, R.D. Callander and D., Clive (1994) Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: A comparison to Salmonella responses. Environ. Mol. Mutagen., 24, 51-60.
2. Benedict W.F., M.S. Baker, L. Haroun, E. Choi and B.N. Ames (1977) Mutagenicity of cancer chemotherapeutic agents in the Salmonella/microsome test, Cancer Res., 37, 2209-2213.
3. Boudvillain, M., R. Dalbies, C. Aussourd and M. Leng (1995) Intrastrand cross-links are not formed in the reaction between transplatin and native DNA: relation with the clinical inefficiency of transplatin, Nucleic Acids Res., 23, 2381-2388.
4. Brabec, V. and M. Leng (1993) DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues, Proc. Natl. Acad. Sci, USA, 90, 5345-5349.
5. Bradley, L.J., K.J. Yarema, S.J. Lippard and J.M. Essigmann (1993) Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II), Biochemistry, 32, 982-988.
6. Brendel, M. and A. Ruhland (1984) Relationships between functionality and genetic toxicology of selected DNA-damaging agents, Mutation Res., 133, 51-85.
7. Brown, S.J., P.J. Kellett and S.J. Lippard (1993) Ixrl, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin, Science, 261, 603-5.
8. Bubley, G.J., B.P. Ashburner and B.A. Teicher (1991) Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells, Mol. Carcinogen., 4, 397-406.
9. Bubley, G.J., B.A. Teicher, G.K. Ogata, L.S. Sandoval and T. Kusumoto (1994) Differences in in vivo and in vitro sequence-specific sites of cisplatin-DNA adduct formation and detection of a dose-response relationship, Biochem. Pharmacol., 48, 145-53.
10. Burchenal, J H, K. Kalaher, K. Dew and L. Lokys (1987) Rationale for development of platinum analogues, Cancer Treat. Rep., 63, 1493-1498.
11. Cariello, N.F., J.A. Swenberg, A. De Bellis and T.R. Skopek (1991) Analysis of mutations using PCR and denaturing gradient gel electrophoresis, Environ. Mol. Mutagen., 18, 249-54.
12. Chaney, S.G., S. Wyrick and G.K. Till (1990) In vitro biotransformation of tetrachloro(D,L-trans) 1 ,2-diaminohexaneplatinum(IV) (tetraplatin) in rat plasma, Cancer Res., 50, 4539-4545.
13. Chibber, R. and M.J. Ord (1989) The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin, Eur. J. Cancer Clin. Oncol., 25, 27-33.
14. Cizeau, J, M. Decoville, M. Leng and D. Locker (1994) Deletions induced in the white and vermilion genes of Drosophila melanogaster by the antitumor drug cis-dichlorodiammineplatinum(II), Mutation Res., 311, 31-8.
15. de Boer, J.G. and B.W. Glickman (1989) Sequence specificity of mutation induced by the anti-tumor drug cisplatin in the CHO aprt gene, Carcinogenesis, 10, 1363-1367.
16. de Boer, J.G. and B.W. Glickman (1992) Mutations recovered in the Chinese hamster aprt gene after exposure to carboplatin: a comparison with cisplatin, Carcinogenesis, 13, 15-17.
17. Eastman, A., N. Schulte, N. Sheibani and C.M. Sorenson (1988) Mechanisms of resistance to platinum drugs, in: M. Nicolini (Ed.), Platinum and other metal coordination compounds in cancer chemotherapy, Martinus Nijhoff, Boston, pp. 178-196.
18. Forsti, A. and K. Hemminki (1986) Unique properties of cisplatin in reactions with nucleophiles, IARC Sci. Pub, 78, 101-110.
19. Fujiwara, Y, M. Nakamura and S. Yokoo (1993) A new anticancer platinum compound, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells, Br. J. Cancer, 67, 1285-1292.
20. Giurgiovich, A.J., B.A. Diwan, L.M. Anderson and M.C. Poirier (1995) Tumorigenic levels of cisplatin induce rat fetal DNA adducts by prenatal exposure. Environ. Mol. Mutagen., 25 (Suppl. 25), 18.
21. Greene, M.H. (1992) Is cisplatin a human carcinogen? J. Natl. Cancer Inst., 34, 306-312.
22. Hanawalt, P.C. (1994) Transcription-coupled repair and human disease, Science, 266, 1957-1958.
23. Hannan, M.M. (1988) A comparative study of the cytotoxic and genotoxic effects of cisplatin and its analogue, TNO-6, in yeast, Mutation Res., 198, 69-72.
24. Harrap, K.R. (1995) Initiatives with platinum-and quinazoline-based antitumor molecules - Fourteenth Bruce F. Cain Memorial Award Lecture, Cancer-Res. 55, 2761-2768.
25. Hemminki, K. (1993) DNA adducts, mutations and cancer, Carcinogenesis, 14, 2007-2012.
26. Hill, B.T, K.J. Scanlon, J. Hansson, A. Harstrick, M. Pera, A.M. Fichtinger-Schepman and S.A. Shellard (1994) Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur. J. Cancer. 30A, 832-837.
27. Huang, J.C., D.B. Zamble, J.T. Reardon, S.J. Lippard and A. Sancar (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease, Proc. Natl. Acad. Sci. USA, 91, 10394-10398.
28. IARC (1981) IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Vol. 26, Some Antineoplastic and Immunosuppressive Agents. IARC, Lyon, France, pp. 151-164.
29. IARC (1987) IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, An updating of Vols. 1-42. Suppl. 7. IARC, Lyon, France, pp. 170-171.
30. Ioannidou, E., T. Lialiaris, D. Mourelatos and J. Dozi-Vassiliades (1989) Synergistic induction of cytogenetic damage by alkylating neoplasties and 5-azacytidine in human lymphocytes. Environ. Mol. Mutagen., 14, 6-12.
31. Islas, A.L., F.J. Baker and P.C. Hanawalt (1994) Transcription-coupled repair of psoralen cross-links but not monoadducts in Chinese hamster ovary cells, Biochemistry, 33, 10794-9.
32. Jirsova, K and V. Mandys (1994) Induction of micronuclei and granular chromatin condensation in human skin fibroblasts influenced by cisplatin (cis-DDP) in vitro, Mutation Res., 310, 37-44.
33. Jones, J.C., W.C. Zhen, E. Reed, R.J. Parker, A. Sancar and V.A. Bohr (1991) Gene specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells, J. Biol. Chem. 266, 7101-7107.
34. Kelland, L.R. and M.J. McKeage (1993) Platinum drugs currently in clinical trial, Curr. Opin. Invest. Drugs, 2, 571-580.
35. Marples, B, H. Adomat, P.C. Billings, N.P. Farrell, C.J. Koch and K.A. Skov (1994) Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms. Anticancer Drug Des. 9, 389-399.
36. Mis, J.R. and B.A. Kunz (1990) Analysis of mutations induced in the SUP4-o gene of Saccharomyces cerevisiae by cis-diammine dichloroplatinum(II), Carcinogenesis, 11, 633-638.
37. Nicklas, J.A., M.J. Lippert, T.C. Hunter, J.P. O'Neill and R.J. Albertini (1991) Analysis of human HPRT deletion mutations with X-linked probes and pulsed field gel electrophoresis, Environ. Mol. Mutagen., 18, 270-273.
38. Oliver, R.T. (1994) Testicular cancer, Curr. Opin. Oncol., 6, 285-291.
39. Papadopoulo, D., A. Laquerbe, C. Guillouf and E. Moustacchi (1993) Molecular spectrum of mutations induced at the HPRT locus by a cross-linking agent in human cell lines with different repair capacities. Mutation Res. 294, 167-177.
40. Pederson-Bjergaard, J., G. Daugaard, S.W. Hansen, P. Philip, S.O. Larsen and M. Rorth (1991) Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ-cell tumors, Lancet, 338, 359-363.
41. Perera, F.P., R.J. Motzer, D. Tang, E. Reed, R. Parker, D. Warburton, P. O'Neill, R. Albertini, W.L. Bigbee, R.H. Jensen, R. Santella, W.Y. Tsai, G. Simon-Cereijido, C. Randall and G. Bosl (1992) Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy, Cancer Res., 52, 3558-2565.
42. Pillaire, M.J., A. Margot, G. Villani, A. Sarasin, M. Defais and A. Gentil (1994) Mutagenesis in monkey cells of a vector containing a single d(GPG) cis-diamminedichloroplatinum(II) adduct placed on codon 13 of the human H-ras proto-oncogene, Nucleic Acid Res., 22, 2519-25124.
43. Roberts, J.J., R.J. Knox, M.F. Pear, F. Friedlos and P A Lyell (1988) In: M Nicolini (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy Nijhoff, Boston, pp 16-31.
44. Quintana, E., J. Pertusa, R. Gonzalez, J. Renau-Piqueras (1994) Carboplatin treatment induces dose-dependent increases in the frequency of micronuclei in Ehrlich ascites tumor cells. Mutation Res., 322, 55-60.
45. Sage, E., E.A. Drobetsky and E. Moustacchi (1993) 8-methoxypsoralen-induced mutations are highly targeted at crosslinkable sites of photoaddition on the non-transcribed strand of a mammalian chromosomal gene, EMBO J. 12, 197-402.
46. Sanderson, B.J.S., K.J. Johnson and W.D. Henner (1991) Dose-dependent cytotoxic and mutagenic effects of antineoplastic alkylating agents on human lymphoblastoid cells. Environ. Mol. Mutagen, 17, 238-243.
47. Sip, M., A. Schwarz, F. Vovelle, M. Ptak and M. Leng (1992) Distortions induced in DNA by cis-platinum interstrand adducts. Biochemistry, 31, 2508-2513.
48. Sundquist, W.I., S.J. Lippard and B.D. Stollar (1986) Binding of cis-and trans-diamminedichloroplatinum(II) to deoxyribonucleic acid exposes nucleosides as measured immunochemically with anti-nucleoside antibodies, Biochemistry, 25, 1520-4.
49. Taylor, R.T., J.H. Carver, M.L. Hanna and D.L. Wandres (1979) Platinum-induced mutations 8-azaguanine resistance in Chinese hamster ovary cells, Mutation Res., 67, 65-80.
50. Treiber, D.K., X. Zhai, H-M Jantzen and J.M. Essigman (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor), Proc. Natl. Acad. Sci. USA, 91, 5672-5676.
51. Turnbull, D., N.C Popescu, J.A., DiPaolo and B.C. Myhr (1979) cis-Platinum(II)diamine dichloride causes mutation, transformation, and sister-chromatid exchanges in cultured mammalian cells, Mutation Res., 66, 267-275.
52. Vogel, E.W. and M.J.M. Nivard (1994) The subtlety of alkylating agents in reactions with biological macromolecules. Mutation Res., 305, 13-32.
53. Weiss, R.B. and M C Christian (1993) New cisplatin drugs in development. Drugs, 46, 360-377.
54. Yang, S.C., J.G. Lin, C.C. Chiou, L.Y. Chen and J. Yang (1994) Mutation specificity of 8-methoxypsoralen plus 2 doses of UVA irradiation in the HPRT gene in diploid human fibroblasts, Carcinogenesis 15, 201-7.
55. Yarema, K.J., J.M. Wilson, S.J. Lippard and J.M. Essigman (1994) Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs, J. Mol. Biol., 236, 1034-1048.
56. Zambie, D.B. and S.J. Lippard (1995) Cisplatin and DNA repair in cancer chemotherapy, Trends Biochem. Sci., 20, 435-439.
57. Zastawny, T.H., W. Olejniczak, R. Olinski (1993) cis-DDP induced alteration of DNA structure studied by scanning tunneling microscopy, Acta Biochim. Pol., 40, 555-558.
58. Zolan, M.E., C.A. Smith and P.C. Hanawalt (1984) Formation and repair of furocoumarin adducts in a deoxyribonucleic acid and bulk deoxyribonucleic acid of monkey cells, Biochemistry, 23, 63-69.
59. Zhen, W., C.J. Link, P.M. O'Connor, E. Reed, R. Parker, S.B. Howell and V. Bohr (1992) Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines, Mol. Cell. Biol., 12, 3689-3698.